Blinatumomab + Asciminib for Philadelphia Chromosome Positive Leukemia
Trial Summary
Asciminib has shown effectiveness in treating chronic myeloid leukemia (CML) in patients who have not responded to at least two other treatments, with better results and fewer side effects compared to another drug, bosutinib. It is particularly effective for patients with specific mutations that make other treatments less effective.
12345The trial protocol does not specify whether you need to stop taking your current medications. However, if you have taken investigational antileukemic or chemotherapy agents in the last 7 days, you may need to wait until you recover from any side effects before joining the study.
This drug combination is unique because Asciminib is a novel type of drug that specifically targets a unique part of the BCR-ABL1 protein, which is often resistant to other treatments, while Blinatumomab helps the immune system attack cancer cells. Asciminib's ability to target the myristoyl pocket of the BCR-ABL1 protein makes it effective against mutations that other drugs can't treat.
13458Asciminib has been studied in patients with chronic myeloid leukemia and has shown a generally favorable safety profile. Common side effects include increased pancreatic enzymes, low platelet counts, high blood pressure, and low white blood cell counts. Most side effects occurred in the first year of treatment, and the likelihood of new side effects decreased over time.
45678Eligibility Criteria
This trial is for patients with a type of leukemia known as Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Specific eligibility criteria are not provided, but typically participants would need to meet certain health standards and may be required to have tried other treatments first.Participant Groups
- Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) in adults previously treated with ≥2 tyrosine kinase inhibitors (TKIs)
- Ph+ CML in CP with the T315I mutation
- newly diagnosed Ph+ CML in CP
- Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) in adults previously treated with ≥2 tyrosine kinase inhibitors (TKIs)
- Ph+ CML in CP with the T315I mutation